Pulse nav.journalClub Trends Entdecken Fragen Forschende

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Datenschutz

Start Entdecken nav.journalClub Trends

⌘+K

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC | Synapse

June 2, 2024

Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC

Key Points

Key points are not available for this paper at this time.

Abstract

Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (

Like

Bookmark

Share

Cite This Study

Lu et al. (Sun,) studied this question.

synapsesocial.com/papers/68e66854b6db6435875f4b86 https://doi.org/https://doi.org/10.1056/nejmoa2402614

Like

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1International Association for the Study of Lung Cancer (IASLC)2021 · 6 citations
2AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer2014 · 2,222 citations
3Clinical outcomes and radiation pneumonitis after concurrent <scp>EGFR</scp>‐tyrosine kinase inhibitors and radiotherapy for unresectable stage <scp>III</scp> non‐small cell lung cancer2021 · 32 citations
4Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC2023 · 106 citations
5Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L2021 · 36 citations